Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Safety and Outcomes in 100 Consecutive Donation After Circulatory Death Liver Transplants Using a Protocol That Includes Thrombolytic Therapy.

Bohorquez H, Seal JB, Cohen AJ, Kressel A, Bugeaud E, Bruce DS, Carmody IC, Reichman TW, Battula N, Alsaggaf M, Therapondos G, Bzowej N, Tyson G, Joshi S, Nicolau-Raducu R, Girgrah N, Loss GE.

Am J Transplant. 2017 Aug;17(8):2155-2164. doi: 10.1111/ajt.14261. Epub 2017 Apr 11.

PMID:
28276658
2.

Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.

Levitsky J, Verna EC, O'Leary JG, Bzowej NH, Moonka DK, Hyland RH, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault NA.

N Engl J Med. 2016 Nov 24;375(21):2106-2108. No abstract available.

3.

Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.

Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK, Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith JW, Levine DL, Traum D, Ho S, Valiga ME, Johnson GS, Doo E, Lok AS, Chang KM; Hepatitis B Research Network.

Gastroenterology. 2016 Mar;150(3):684-695.e5. doi: 10.1053/j.gastro.2015.11.050. Epub 2015 Dec 10.

4.

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M; ASTRAL-4 Investigators.

N Engl J Med. 2015 Dec 31;373(27):2618-28. doi: 10.1056/NEJMoa1512614. Epub 2015 Nov 16.

5.

AASLD guidelines for treatment of chronic hepatitis B.

Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases.

Hepatology. 2016 Jan;63(1):261-83. doi: 10.1002/hep.28156. Epub 2015 Nov 13. No abstract available.

PMID:
26566064
6.

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; EMERGE study group.

J Hepatol. 2014 Dec;61(6):1238-46. doi: 10.1016/j.jhep.2014.07.022. Epub 2014 Jul 24.

PMID:
25064437
7.

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.

Flamm SL, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM.

J Clin Gastroenterol. 2015 Apr;49(4):336-44. doi: 10.1097/MCG.0000000000000150.

PMID:
24828357
8.

Liver transplantation at the ochsner clinic: quality and outcomes improvement.

Therapondos G, Bohorquez H, Bruce DS, Bzowej NH, Carmody IC, Cohen AJ, Girgrah N, Joshi S, Reichman TW, Loss GE Jr.

Ochsner J. 2013 Fall;13(3):413-8. Review.

9.

Acute liver failure caused by herpes simplex virus in a pregnant patient: is there a potential role for therapeutic plasma exchange?

Holt EW, Guy J, Gordon SM, Hofmann JC, Garcia-Kennedy R, Steady SL, Bzowej NH, Frederick RT.

J Clin Apher. 2013 Dec;28(6):426-9. doi: 10.1002/jca.21287. Epub 2013 Jul 16.

PMID:
23857723
10.

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A.

Lancet Infect Dis. 2013 May;13(5):401-8. doi: 10.1016/S1473-3099(13)70033-1. Epub 2013 Mar 15.

PMID:
23499158
11.

Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.

Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J.

Liver Transpl. 2013 Jun;19(6):594-601. doi: 10.1002/lt.23628. Epub 2013 Apr 9.

12.

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.

Wedemeyer H, Jensen D, Herring R Jr, Ferenci P, Ma MM, Zeuzem S, Rodriguez-Torres M, Bzowej N, Pockros P, Vierling J, Ipe D, Munson ML, Chen YC, Najera I, Thommes J; PROPEL Investigators.

Hepatology. 2013 Aug;58(2):524-37. doi: 10.1002/hep.26274. Epub 2013 Jun 26.

PMID:
23348636
13.

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.

Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D; ELEVATE Study Group.

N Engl J Med. 2012 Aug 23;367(8):716-24. doi: 10.1056/NEJMoa1110709.

14.

Optimal Management of the Hepatitis B Patient Who Desires Pregnancy or Is Pregnant.

Bzowej NH.

Curr Hepat Rep. 2012 Jun;11(2):82-89. Epub 2012 May 26.

15.

Response-guided telaprevir combination treatment for hepatitis C virus infection.

Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F; ILLUMINATE Study Team.

N Engl J Med. 2011 Sep 15;365(11):1014-24. doi: 10.1056/NEJMoa1014463. Erratum in: N Engl J Med. 2011 Oct 20;365(16):1551.

16.

The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis.

Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C.

J Clin Gastroenterol. 2012 Feb;46(2):155-61. doi: 10.1097/MCG.0b013e318228b781.

PMID:
21814143
17.

Telaprevir for retreatment of HCV infection.

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team.

N Engl J Med. 2011 Jun 23;364(25):2417-28. doi: 10.1056/NEJMoa1013086.

18.

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team.

N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912.

19.

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.

Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR; PHOENIX Study Group.

Liver Transpl. 2011 May;17(5):528-38. doi: 10.1002/lt.22271.

20.

Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series.

Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C.

Dig Dis Sci. 2011 Feb;56(2):578-85. doi: 10.1007/s10620-010-1444-6. Epub 2010 Nov 3.

PMID:
21046244

Supplemental Content

Loading ...
Support Center